Fig. 2

TF interacts with INTB1 to reduce TG content in adipocytes. Deprived differentiated adipocytes from c3H10T1/2 were treated with TF 50 µM or vehicle (CT) or co-treated with a specific INTB1 blocking antibody (HMB1), RGDS, eptifibatide (EPT) or cilengitide (CIL) for the indicated times. A, B Representative immunoblots and densitometric analysis of phosphorylated INTB1 at Thr788/9 (P-INTB1) vs total INTB1. Tubulin content is shown as endogenous control C, D quantification of TG contained in LD, stained with AdipoRed. N = 8–12. Data are shown as mean ± SEM, *p < 0.05 vs CT, #p < 0.05 vs TF